A Phase 2 Study to Evaluate the Dose and Pharmacodynamic Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy

This study is ongoing, but not recruiting participants.

Sponsor:

Information provided by (Responsible Party):

Ultragenyx Pharmaceutical Inc

ClinicalTrials.gov Identifier:

NCT01517880

First received: January 17, 2012

Last updated: November 2, 2012

Last verified: November 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	August 2013
Estimated Primary Completion Date:	June 2013 (Final data collection date for primary outcome measure)